Soft inflationUS inflation came in softer than expected today and the S&P Bitech ETF is now up 26% since two weeks prior to the announcement of the merger between AEZS and CZO. Only about two weeks in the last over two years has the S&P Biotech ETF been higher than this morning. If Gilles bought biotech assets when they were trading below cash just before they are about to trade above cash again due to market conditions and as AEZS's diagnostic and pipeline enters human testing Gilles bought a gold mine. Gilles also purchased AEZS's substantial taxloss carryforwards as PGX makes moves to commercialization, etc.